163 related articles for article (PubMed ID: 38229170)
1. Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study.
de Souza S; Williams R; Nikiphorou E
BMC Rheumatol; 2024 Jan; 8(1):1. PubMed ID: 38229170
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
Ann Rheum Dis; 2024 Apr; ():. PubMed ID: 38594056
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
Venetsanopoulou AI; Voulgari PV; Drosos AA
Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
[TBL] [Abstract][Full Text] [Related]
4. Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs.
Ahn SS; Han M; Jung I; Kim HW
Clin Exp Rheumatol; 2023 Sep; 41(9):1908-1916. PubMed ID: 36995320
[TBL] [Abstract][Full Text] [Related]
5. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
6. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Cho SK; Kim H; Song YJ; Kim HW; Nam E; Lee SS; Lee HS; Park SH; Lee YA; Park MC; Chang SH; Kim HA; Kwok SK; Kim HR; Kim HS; Yoon BY; Uhm WS; Kim YG; Kim JH; Lee J; Choi J; Sung YK
Korean J Intern Med; 2023 Jul; 38(4):546-556. PubMed ID: 37334513
[TBL] [Abstract][Full Text] [Related]
8. Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK.
Tian Z; Kearsley-Fleet L; Galloway J; Watson K; Lunt M; ; Hyrich KL
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38748995
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
Tsai JJ; Liu LT; Chen CH; Chen LJ; Wang SI; Wei JC
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37479495
[TBL] [Abstract][Full Text] [Related]
10. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.
Liu L; Yan YD; Shi FH; Lin HW; Gu ZC; Li J
Front Immunol; 2022; 13():977265. PubMed ID: 36248913
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
13. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Reddy V; Cohen S
Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
[TBL] [Abstract][Full Text] [Related]
14. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
[TBL] [Abstract][Full Text] [Related]
15. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
16. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
[TBL] [Abstract][Full Text] [Related]
17. Janus Kinase Inhibitors: Next-Generation Treatment for Uveitis.
El-Shabrawi Y; Rath T; Heiligenhaus A
Klin Monbl Augenheilkd; 2022 May; 239(5):695-701. PubMed ID: 35426113
[TBL] [Abstract][Full Text] [Related]
18. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
[TBL] [Abstract][Full Text] [Related]
19. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis.
Temmoku J; Migita K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Watanabe H; Miyata M
Medicine (Baltimore); 2022 Oct; 101(42):e31161. PubMed ID: 36281115
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
Onishi A; Yamada H; Yamamoto W; Watanabe R; Hara R; Katayama M; Okita Y; Maeda Y; Amuro H; Son Y; Yoshikawa A; Hata K; Hashimoto M; Saegusa J; Morinobu A
Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37988163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
